ScandiBio Featured on Life Science Sweden’s 2026 Phase III Watchlist
Sweden’s life science sector is entering a decisive phase. A recent overview from Life Science Sweden highlights that a growing number of Swedish life science companies…
-
-
First 100 Patients Enrolled in Phase 3 Trial of ScandiBio Therapeutics AI-developed Drug for Alzheimer’s Disease
Stockholm, 4 December, 2025 – ScandiBio Therapeutics AB today announced that the first 100 patients have been recruited to the multi-centre, phase 3 human clinical trial…
-
ScandiBio Therapeutics AB Announces Initiation of Phase 3 Clinical Trial of Combined Metabolic Activators (CMA) for Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia, which is a general term for memory loss and other cognitive impairments that are significant enough…
-
Metabolic Activators Therapy Improve Liver Fat in NAFLD Patients
A phase-2 human clinical study showed that patients with nonalcoholic fatty liver disease (NAFLD) experienced a significant reduction in liver fat when receiving the combination of…
-
Phase 2 human clinical trial shows that metabolic activators improve cognitive function in Parkinson’s disease patients
ScandiBio Therapeutics announced Phase 2 clinical trial results from the study on the open-access server medRxiv.org. The results: Combined Metabolic Activators Improve Cognitive Functions without Altering…
-
Phase 2 human clinical trial shows that metabolic activators improve cognitive function in Alzheimer’s disease patients
ScandiBio Therapeutics announced Phase 2 clinical trial results from the study on the open-access server medRxiv.org. The study: Combined Metabolic Activators Improves Cognitive Functions in Alzheimer’s…
-
The results of a phase I study of CMCS have been published
The results of a Phase I study have been published in the journal Molecular Systems Biology describing the kinetics of the Combined Metabolic Cofactor Supplementation (CMCS)…
-
Phase 3 human clinical trial shows that metabolic activators accelerate recovery in COVID-19 patients
The Swedish biotechnology company ScandiBio Therapeutics today announced results from the study. The study conducted in Turkey was published on February 20 on medRxiv, a preprint…
-
Phase 2 human clinical trial shows that metabolic activators reduces liver fat in NAFLD patients
ScandiBio Therapeutics announced results from the study “Combined Metabolic Activators Reduces Liver Fat in Nonalcoholic Fatty Liver Disease” were published on Cell Press Sneak Peek, a…
-
Phase 2 human clinical trial shows that metabolic activators reduces recovery time in COVID-19 patients by nearly 30%
ScandiBio Therapeutics has completed a Phase II study based on treatment of patients with COVID-19. Patients with mild-to-moderate COVID-19 experienced a 29% reduction in recovery time…
